China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.54−0.01 (-1.43%)
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
China Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
China Pharma's ebitda for the twelve months ending Jun 30, 2026 was -$1.44M. For fiscal 2025 it was -$1.74M. The highest annual figure on record is $26.17M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.74M | – |
| FY2024 | Dec 31, 2024 | -$1.97M | -107617.7% |
| FY2023 | Dec 31, 2023 | $1.83K | – |
| FY2022 | Dec 31, 2022 | -$848.44K | -473.3% |
| FY2021 | Dec 31, 2021 | $227.31K | +124.7% |
| FY2020 | Dec 31, 2020 | $101.18K | – |
| FY2019 | Dec 31, 2019 | -$17.48M | – |
| FY2018 | Dec 31, 2018 | -$7.19M | – |
| FY2017 | Dec 31, 2017 | -$15.39M | – |
| FY2016 | Dec 31, 2016 | -$5.08M | – |
| FY2015 | Dec 31, 2015 | -$10.70M | – |
| FY2014 | Dec 31, 2014 | -$36.97M | – |
| FY2013 | Dec 31, 2013 | -$16.99M | -330.6% |
| FY2012 | Dec 31, 2012 | $7.37M | -68.2% |
| FY2011 | Dec 31, 2011 | $23.20M | -11.3% |
| FY2010 | Dec 31, 2010 | $26.17M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$329.99K | – |
| Q1 FY2026 | Mar 31, 2026 | -$136.69K | – |
| Q4 FY2025 | Dec 31, 2025 | -$702.77K | – |
| Q3 FY2025 | Sep 30, 2025 | -$272.11K | – |
| Q2 FY2025 | Jun 30, 2025 | -$331.26K | – |
| Q1 FY2025 | Mar 31, 2025 | -$429.31K | – |
| Q4 FY2024 | Dec 31, 2024 | -$747.96K | – |
| Q3 FY2024 | Sep 30, 2024 | -$388.31K | – |
| Q2 FY2024 | Jun 30, 2024 | -$652.27K | -373.4% |
| Q1 FY2024 | Mar 31, 2024 | -$182.25K | -164.5% |
| Q4 FY2023 | Dec 31, 2023 | -$488.66K | – |
| Q3 FY2023 | Sep 30, 2023 | -$30.45K | – |
| Q2 FY2023 | Jun 30, 2023 | $238.53K | – |
| Q1 FY2023 | Mar 31, 2023 | $282.40K | – |
| Q4 FY2022 | Dec 31, 2022 | -$529.59K | -953.8% |
| Q3 FY2022 | Sep 30, 2022 | -$24.32K | -111.4% |
| Q2 FY2022 | Jun 30, 2022 | -$96.38K | – |
| Q1 FY2022 | Mar 31, 2022 | -$198.16K | -5428.3% |
| Q4 FY2021 | Dec 31, 2021 | $62.03K | – |
| Q3 FY2021 | Sep 30, 2021 | $214.05K | – |
| Q2 FY2021 | Jun 30, 2021 | -$52.49K | -107.2% |
| Q1 FY2021 | Mar 31, 2021 | $3.72K | -93.4% |
| Q4 FY2020 | Dec 31, 2020 | -$400.40K | – |
| Q3 FY2020 | Sep 30, 2020 | -$279.20K | -785.6% |
| Q2 FY2020 | Jun 30, 2020 | $724.13K | +2541.0% |
| Q1 FY2020 | Mar 31, 2020 | $56.64K | -87.7% |
| Q4 FY2019 | Dec 31, 2019 | -$18.01M | – |
| Q3 FY2019 | Sep 30, 2019 | $40.73K | – |
| Q2 FY2019 | Jun 30, 2019 | $27.42K | – |
| Q1 FY2019 | Mar 31, 2019 | $461.28K | -36.0% |
| Q4 FY2018 | Dec 31, 2018 | -$6.75M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.51K | – |
| Q1 FY2018 | Mar 31, 2018 | $720.74K | +5548.0% |
| Q4 FY2017 | Dec 31, 2017 | -$12.85M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.32M | – |
| Q1 FY2017 | Mar 31, 2017 | $12.76K | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$693.01K | – |
See a number that looks wrong?